Target AudienceNeuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates, and Nursing Professionals.
Statement of Need/Program OverviewThe Society for Neuro-Oncology’s Annual Meeting is the largest and most influential meeting for multidisciplinary collaboration in the field of Neuro-Oncology. The latest advances in Central Nervous System (CNS) cancers are shared with an international audience that includes a variety of sub-specialties involved in basic and translational research, clinical as well as symptom management research. The meeting fosters opportunities to explore collaborations that will positively influence outcomes for patients with CNS cancers. This year’s meeting will highlight the theme of Neuro-Oncology at the Intersections: Multidisciplinary Approaches to Improve Patient Outcomes. This activity is a collaboration of researchers and clinicians disseminating new knowledge to healthcare professionals in order to provide the highest quality of patient care to improve patient outcomes. The goal is to provide healthcare professionals with updated viewpoints, strategies, collaboration opportunities and an increased knowledge base to maximize treatment and improve outcomes for brain tumor patients.
Educational Objectives
- Summarize the latest basic science discoveries in the field of neuro-oncology.
- Discuss advances in multidisciplinary diagnosis and treatment of patients with CNS malignancies.
- Define advances and challenges in clinical trial design, delivery, and treatment for patients with CNS malignancies.
- Identify new advances in the multidisciplinary care of pediatric, adolescent, and young adult patients with CNS malignancies.
- Discuss how to use the advances of artificial intelligence and machine learning models in the care of patients with CNS malignancies.
Program AgendaPlease
click here.
Physician Accreditation StatementThe Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit DesignationThe Society for Neuro-Oncology designates this live activity for a maximum of 12.00
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
SNO Contact InformationFor more information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at
melesa@soc-neuro-onc.org.
Instructions to Receive CreditIn order to receive credit for this activity, the participant must have attended the sessions in-person (you cannot claim CME for on-demand sessions), complete the annual meeting program evaluation and session evaluations by logging in to this website or the conference mobile app by using the users registration login.
Click here for step-by-step instructions.
Deadline to claim CE Credit is Monday, February 12, 2024.
Refund/Cancellation PolicyThe deadline for cancellations with refund is Thursday, November 2, 2023. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.
Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category.
Payment must be received in full before access to the meeting can be granted.
Email all cancellation and transfer requests to Program Registrar Caroline Noor,
caroline@soc-neuro-onc.org.
Disclosure of Relevant Financial RelationshipsThe Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO.
Please find the list of disclosures
here.
Disclosure of Unlabeled UseThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DisclaimerParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.